Back
95
Day Range
$9.01
$9.50
52-Week Range
$6.19
$13.16
Volume
856,044
50D / 200D Avg
$9.04
/
$9.48
Prev Close
$9.23
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 6.7 | 0.4 |
| P/B | 3.6 | 2.9 |
| ROE % | 85.7 | 3.7 |
| Net Margin % | 78.2 | 3.9 |
| Rev Growth 5Y % | 38.8 | 10.0 |
| D/E | 0.4 | 0.2 |
Analyst Price Target
Hold
$24.25
+157.4%
Low: $23.00
High: $26.00
Forward P/E
19.4
Forward EPS
$0.49
EPS Growth (est.)
+0.0%
Est. Revenue
140 M
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$3.42
$3.00 – $4.42
|
410 M | 5 |
| FY2029 |
$3.04
$2.67 – $3.94
|
360 M | 2 |
| FY2028 |
$2.51
$1.60 – $4.36
|
310 M | 7 |
Key Takeaways
Revenue grew 38.84% annually over 5 years — strong growth
ROE of 85.66% indicates high profitability
Net margin of 78.17% shows strong profitability
Debt/Equity of 0.41 — conservative balance sheet
Negative free cash flow of -2.43M
P/E of 6.65 — trading at a low valuation
Growth
Revenue Growth (5Y)
38.84%
Revenue (1Y)350.91%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
85.66%
ROIC-1.46%
Net Margin78.17%
Op. Margin-3.98%
Safety
Debt / Equity
0.41
Current Ratio5.68
Interest Coverage-0.53
Valuation
P/E Ratio
6.65
P/B Ratio3.58
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 350.91% | Revenue Growth (3Y) | 96.90% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 38.84% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 106.47M | Net Income (TTM) | 83.23M |
| ROE | 85.66% | ROA | 29.23% |
| Gross Margin | 80.71% | Operating Margin | -3.98% |
| Net Margin | 78.17% | Free Cash Flow (TTM) | -2.43M |
| ROIC | -1.46% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.41 | Current Ratio | 5.68 |
| Interest Coverage | -0.53 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 6.65 | P/B Ratio | 3.58 |
| P/S Ratio | 5.19 | PEG Ratio | -0.04 |
| EV/EBITDA | N/A | Dividend Yield | 0.00% |
| Market Cap | 553.06M | Enterprise Value | 553.86M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 106.47M | 23.61M | 27.46M | 10.16M | 28.65M |
| Net Income | 83.23M | -105.51M | -46.05M | -26.77M | -8.56M |
| EPS (Diluted) | 1.35 | -2.28 | -1.30 | -0.78 | -2.11 |
| Gross Profit | 85.93M | 16.20M | 24.52M | 9.94M | 26.59M |
| Operating Income | -4.23M | -87.00M | -49.60M | -42.57M | 7.73M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 284.73M | 178.13M | 172.33M | 115.34M | 132.94M |
| Total Liabilities | 130.07M | 138.46M | 110.46M | 40.22M | 5.82M |
| Shareholders' Equity | 154.66M | 39.67M | 61.86M | 75.12M | 127.12M |
| Total Debt | 63.21M | 60.30M | 43.77M | 18.78M | 1.61M |
| Cash & Equivalents | 62.41M | 33.79M | 43.05M | 65.47M | 112.35M |
| Current Assets | 223.01M | 86.03M | 86.94M | 92.83M | 115.06M |
| Current Liabilities | 39.28M | 34.07M | 73.72M | 12.02M | 4.23M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
#8 of 658
Recent Activity
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026